R3R01
Phase 2Small molecule
R3R01 is one of 6 small molecule programs targeting Diabetic Kidney Disease. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Diabetic Kidney Disease
#DrugCompanyPhaseTrials
1Kerendia
BayerApproved
Jardiance
Boehringer IngelheimApproved
Mazdutide
Eli LillyPhase 3
Angiotensin Receptor Blocker
NNational University of Ireland, Galway, Ireland
Phase 3
R3R01
RRiver 3 Renal Corp.
Phase 2
AP303 150μg
AAlebund Pharmaceuticals
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for R3R01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRiver 3 Renal Corp.